7.22
price down icon2.30%   -0.17
after-market Handel nachbörslich: 7.12 -0.10 -1.39%
loading
Schlusskurs vom Vortag:
$7.39
Offen:
$7.23
24-Stunden-Volumen:
58,669
Relative Volume:
0.18
Marktkapitalisierung:
$5.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.93M
KGV:
-0.0271
EPS:
-266.137
Netto-Cashflow:
$-15.87M
1W Leistung:
+4.64%
1M Leistung:
-38.97%
6M Leistung:
-97.04%
1J Leistung:
-99.30%
1-Tages-Spanne:
Value
$7.07
$8.18
1-Wochen-Bereich:
Value
$6.54
$8.18
52-Wochen-Spanne:
Value
$6.1478
$1,293.51

Transcode Therapeutics Inc Stock (RNAZ) Company Profile

Name
Firmenname
Transcode Therapeutics Inc
Name
Telefon
857-301-6857
Name
Adresse
6 LIBERTY SQUARE, BOSTON
Name
Mitarbeiter
7
Name
Twitter
Name
Nächster Verdiensttermin
Name
Neueste SEC-Einreichungen
Name
RNAZ's Discussions on Twitter

Vergleichen Sie RNAZ mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
RNAZ
Transcode Therapeutics Inc
7.22 5.75M 0 -14.93M -15.87M -266.14
Biotechnology icon
ONC
Beone Medicines Ltd Adr
257.00 26.69B 3.81B -644.79M -669.77M -6.24
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.82 114.81B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
AKTX
Akari Therapeutics Plc Adr
1.282 41.83M 0 0 0 0.00
Biotechnology icon
VRNA
Verona Pharma Plc Adr
85.54 6.60B 0 -153.72M -103.81M -2.00
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
483.07 65.36B 14.09B 4.50B 2.96B 39.28

Transcode Therapeutics Inc Aktie (RNAZ) Neueste Nachrichten

pulisher
May 29, 2025

(RNAZ) On The My Stocks Page - news.stocktradersdaily.com

May 29, 2025
pulisher
May 28, 2025

Transcode Therapeutics Appoints Dr. Phillip D. Zamore To Science Advisory Board - marketscreener.com

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board - citybiz

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics appoints RNA expert to advisory board - Investing.com

May 28, 2025
pulisher
May 28, 2025

TransCode Therapeutics appoints RNA expert to advisory board By Investing.com - Investing.com Nigeria

May 28, 2025
pulisher
May 28, 2025

Alnylam Co-Founder Who Developed First FDA-Approved RNAi Drug Joins TransCode's Cancer Mission - Stock Titan

May 28, 2025
pulisher
May 24, 2025

TransCode Therapeutics (NASDAQ:RNAZ) Cut to “Sell” at Wall Street Zen - Defense World

May 24, 2025
pulisher
May 23, 2025

Certain Options of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Certain Warrants of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 23, 2025

Certain Common Stock of TransCode Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 24-MAY-2025. - marketscreener.com

May 23, 2025
pulisher
May 19, 2025

When (RNAZ) Moves Investors should Listen - news.stocktradersdaily.com

May 19, 2025
pulisher
May 16, 2025

Analysts Offer Insights on Healthcare Companies: Verve Therapeutics (VERV), Nkarta (NKTX) and Kamada (KMDA) - The Globe and Mail

May 16, 2025
pulisher
May 14, 2025

Transcode Therapeutics (RNAZ) Trading Halted Pending News Announ - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Transcode Therapeutics (RNAZ) Trading Halted Pending News Announcement | RNAZ Stock News - GuruFocus

May 14, 2025
pulisher
May 14, 2025

TransCode Therapeutics (RNAZ) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Abeona Therapeutics (ABEO) Expected to Announce Earnings on Wednesday - Defense World

May 14, 2025
pulisher
May 14, 2025

Intellia Therapeutics (NASDAQ:NTLA) Shares Down 6.1% After Analyst Downgrade - Defense World

May 14, 2025
pulisher
May 12, 2025

Upcoming Stock Splits This Week (May 12 to May 16) – Stay Invested - The Globe and Mail

May 12, 2025
pulisher
May 09, 2025

(RNAZ) Investment Report - news.stocktradersdaily.com

May 09, 2025
pulisher
May 08, 2025

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported - Stock Titan

May 08, 2025
pulisher
May 07, 2025

TransCode Therapeutics Faces Nasdaq Delisting Risk - TipRanks

May 07, 2025
pulisher
May 05, 2025

TransCode Therapeutics Announces Reverse Stock Split - TipRanks

May 05, 2025
pulisher
May 05, 2025

TransCode Plans Massive 28:1 Stock Consolidation: What This Means for Your RNAZ Shares - Stock Titan

May 05, 2025
pulisher
May 05, 2025

US Stocks Likely To Open Lower After S&P 500's 9-Day Streak: 'Any De-Escalation In Trade Tensions Should Be Positive,' Says Expert - Benzinga

May 05, 2025
pulisher
May 05, 2025

Tyson Foods, Ford And 3 Stocks To Watch Heading Into Monday - Benzinga

May 05, 2025
pulisher
May 04, 2025

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split - citybiz

May 04, 2025
pulisher
May 03, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules By Investing.com - Investing.com India

May 03, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

Offerings News Live Feed - Stock Titan

May 02, 2025
pulisher
May 02, 2025

Transcode Therapeutics Announces 1-For-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Announces 1-for-28 Reverse Stock Split - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves reverse stock split to meet Nasdaq rules - Investing.com

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics approves 1-for-28 reverse stock split; shares fall - MSN

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics (RNAZ) Plans 1-for-28 Reverse Stock Split | RNAZ Stock News - GuruFocus

May 02, 2025
pulisher
May 02, 2025

TransCode Therapeutics to Implement 1-for-28 Reverse Stock Split - marketscreener.com

May 02, 2025
pulisher
May 02, 2025

TransCode Plans Major 1:28 Reverse Split, Slashing Shares from 23M to 833K for Nasdaq Listing - Stock Titan

May 02, 2025
pulisher
May 02, 2025

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside - MSN

May 02, 2025
pulisher
May 02, 2025

For Dropbox Inc [DBX], Analyst sees a drop to $30. What next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Direct Digital Holdings Inc [DRCT] is -44.37% lower this YTD. Is it still time to buy? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

CN Energy Group Inc [CNEY] Is Currently 9.75 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Wall Street Analyst Upgrade Rush Street Interactive Inc [RSI]. What else is Wall St. saying - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Kronos Bio Inc [KRON] is a Good Choice for Investors After New Price Target of $1.00 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Glaukos Corporation [GKOS] Revenue clocked in at $383.48 million, down -44.28% YTD: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Republic Digital Acquisition Company [RDAGU] Stock trading around $10.15 per share: What’s Next? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Venture Global Inc [VG] stock Initiated by UBS analyst, price target now $14 - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Hayward Holdings Inc [HAYW] Is Currently 5.18 below its 200 Period Moving Avg: What Does This Mean? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

Market cap of Solaris Energy Infrastructure Inc [SEI] reaches 1.55B – now what? - dbtnews.com

May 02, 2025
pulisher
May 02, 2025

why Astera Labs Inc [ALAB] is a Good Choice for Investors After New Price Target of $111.21 - dbtnews.com

May 02, 2025
pulisher
May 01, 2025

IBN Coverage: TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - Yahoo Finance

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (NASDAQ: RNAZ) Advances Phase 1a Trial of RNA Cancer Therapy TTX-MC138 - The Globe and Mail

May 01, 2025
pulisher
May 01, 2025

TransCode Therapeutics (RNAZ) Advances Clinical Trial of TTX-MC1 - GuruFocus

May 01, 2025

Finanzdaten der Transcode Therapeutics Inc-Aktie (RNAZ)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$1.15
price down icon 0.86%
$580.59
price up icon 1.24%
$308.00
price up icon 0.88%
$36.54
price up icon 1.27%
$4.8111
price up icon 1.29%
$483.07
price down icon 0.38%
Kapitalisierung:     |  Volumen (24h):